Abstract
At present cancer treatment is still a confusing problem. Great progress has been made in anti-tumor agents since a series of small molecules are approved by FDA as anti-tumor drugs. Nitroimidazoles is a kind of radiosensitizer with multiple bioactivities used in cancer treatment since 1950s. In this review, we focus on the development of nitroimidazoles as radiosensitizer, bio-reductive prodrug and other types of anti-tumor agents for cancer therapy, and the mechanism of acting as anti-tumor agents. Finally, we also discuss the prospect and developmental trend of nitroimidazoles as anti-tumor agents.
Keywords: Anti-tumor, 2-Nitroimidazole, Hypoxic cell radiosensitizer, Bio-reductive prodrug, Abl tyrosine kinase inhibitor, nitroimidazoles, synergistic effect, normoxia, chemotherapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Nitroimidazoles as Anti-Tumor Agents
Volume: 11 Issue: 7
Author(s): Kai Liu and Hai-Liang Zhu
Affiliation:
Keywords: Anti-tumor, 2-Nitroimidazole, Hypoxic cell radiosensitizer, Bio-reductive prodrug, Abl tyrosine kinase inhibitor, nitroimidazoles, synergistic effect, normoxia, chemotherapy
Abstract: At present cancer treatment is still a confusing problem. Great progress has been made in anti-tumor agents since a series of small molecules are approved by FDA as anti-tumor drugs. Nitroimidazoles is a kind of radiosensitizer with multiple bioactivities used in cancer treatment since 1950s. In this review, we focus on the development of nitroimidazoles as radiosensitizer, bio-reductive prodrug and other types of anti-tumor agents for cancer therapy, and the mechanism of acting as anti-tumor agents. Finally, we also discuss the prospect and developmental trend of nitroimidazoles as anti-tumor agents.
Export Options
About this article
Cite this article as:
Liu Kai and Zhu Hai-Liang, Nitroimidazoles as Anti-Tumor Agents, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (7) . https://dx.doi.org/10.2174/187152011796817664
DOI https://dx.doi.org/10.2174/187152011796817664 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radioprotective Gene Therapy
Current Gene Therapy Immune and Genetic Mechanisms in COPD: Possible Targets for Therapeutic Interventions
Current Drug Targets Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Titanocene Y - Transport and Targeting of an Anticancer Drug Candidate
Letters in Drug Design & Discovery Tissue Biomarkers for Prostate Cancer Radiation Therapy
Current Molecular Medicine 2-Arylbenzimidazoles as Antiviral and Antiproliferative Agents-Part 2
Medicinal Chemistry Determination of Human Serum α1-Acid Glycoprotein and Albumin Binding of Various Marketed and Preclinical Kinase Inhibitors
Current Medicinal Chemistry Application of Chemistry-Based Functional Proteomics to Screening for Novel Drug Targets
Combinatorial Chemistry & High Throughput Screening Pharmacological Approaches to Targeting Muscarinic Acetylcholine Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Cancer Biology Aspects of Computational Methods & Applications in Drug Discovery
Current Pharmaceutical Design Lung Cancer and Radiological Imaging
Current Radiopharmaceuticals Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer
Current Pharmaceutical Design Extracellular Matrix and Aberrant Signaling in Lung Carcinoma: Role of Fibronectin in the Control of Human Lung Carcinoma Cell Growth,Apoptosis and Resistance to Therapy
Current Signal Transduction Therapy Humoral Immunity in HIV-1 Exposure: Cause or Effect of HIV Resistance?
Current HIV Research The Potential of Receptor for Advanced Glycation End Products (RAGE) as a Therapeutic Target for Lung Associated Diseases
Current Drug Targets The Current Status of Novel PET Radio-Pharmaceuticals in Radiotherapy Treatment Planning of Glioma
Current Pharmaceutical Biotechnology Rho Kinase and Angiogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Blocking the PI3K/PKB Pathway in Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents